Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
NCT ID: NCT00300729
Last Updated: 2009-06-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
319 participants
INTERVENTIONAL
2006-05-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The rationale behind the study consists of preclinical observations of antitumor effect of celecoxib in NSCLC. Inhibition of angiogenesis and proliferation as well as increased apoptosis has been demonstrated. In addition, pilot studies have shown that the combination of chemotherapy and celecoxib is feasible. No unexpected toxicity has been recorded in such trials. Furthermore, a randomized study of indomethacin, prednisolone or placebo in other types of advanced cancer, mainly gastrointestinal, showed a survival advantage for patients receiving antiinflammatory treatment.
Chemotherapy is given according to the current standard of the participating institution. In practice, patients will usually receive either carboplatin + gemcitabine or carboplatin + vinorelbine. Treatment duration with chemotherapy is 4 cycles (cycle length 3 weeks) in the absence of tumour progression or prohibitive toxicity.
Treatment with the study drug starts on the first day of cancer chemotherapy. Maximum treatment duration is one year. Treatment will be stopped earlier in case of objective tumor progression, serious toxicity that is considered to be related to the study drug or if the patient wants to stop treatment.
The size of the study is based on the hypothesis that celecoxib could prolong median survival by 8 weeks as compared to 7.5 months in the placebo group. With standard statistical requirements (type I error 5%, type II error 20%), the calculated number of patients was 760.
The study was supported by the Swedish Lung Cancer Study Group and organized as a multicenter trial, with participation of seven university hospitals and six smaller hospitals. The number of new cases of NSCLC stage IIIB-IV and performance status 0-2 in Sweden is around 1200/year. It was expected that 20% of the patients could be included in the study, which would make completion possible in three years.
The study was opened for randomization on May 31, 2006. Recruitment of patients was lower than expected. The study was closed for further randomization on May 31, 2009, as originally planned. 319 patients were included. Since maximum duration of treatment with the study drug is one year, the code will be broken after May 31, 2010. Data analysis is planned to take place in summer and autumn, 2010.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Celecoxib
Four cycles of combination chemotherapy, usually with carboplatin + gemcitabine or carboplatin + vinorelbine, plus celecoxib 400 mg b.i.d. Treatment with celecoxib is continued after completion of chemotherapy. Maximum treatment duration is one year.
Celecoxib
Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Placebo
Chemotherapy as in arm 1 plus placebo capsules, b.i.d.
Placebo
One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Celecoxib
Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Placebo
One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age at least 18 years. No upper age limit.
* Disease stage IIIB or IV.
* Performance status (WHO) 0-2
* Treatment with curative intent is not possible
* No prior chemotherapy for the present disease
* Planned treatment is palliative chemotherapy
* WBC count at least 3.0, platelet count at least 100
* Bilirubin \< 1.5 \* upper reference limit (URL), ASAT and ALAT \< 3 \* URL (\<5 in case of liver metastases)
* Calculated creatinine clearance at least 40 mg/ml
* Informed oral and written consent
Exclusion Criteria
* Active duodenal ulcer, ongoing gastrointestinal bleeding or inflammatory bowel disease
* Serious heart failure or serious liver disease
* Hypersensitivity so sulfonamides
* Pregnancy
* Lactation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swedish Lung Cancer Study Group
NETWORK
Pfizer
INDUSTRY
University Hospital, Linkoeping
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Swedish Lung Cancer Study Group
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sverre Sörenson, MD, PhD
Role: STUDY_CHAIR
Department of Medicine, Ryhov County Hospital, Jönköping, Sweden, Department of Pulmonary Medicine, University Hospital, Linköping, Sweden, and Department of Medical and Health Sciences, Linköping University, Sweden
Andrea Koch, MD
Role: PRINCIPAL_INVESTIGATOR
Allergy Centre, University Hospital, Linköping, Sweden, Department of Pulmonary Medicine, University Hospital, Linköping, Sweden, and Department of Medical and Health Sciences, Linköping University, Sweden
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pulmonary Medicine and Allergology, Sahlgrenska University Hospital
Gothenburg, , Sweden
Section of Pulmonary Medicine, Ryhov County Hospital
Jönköping, , Sweden
Section of Pulmonary Medicine and Allergology, County Hospital of Kalmar
Kalmar, , Sweden
Department of Pulmonary Medicine, University Hospital
Linköping, , Sweden
Department of Pulmonary Medicine and Allergy, Lund University Hospital
Lund, , Sweden
Section of Pulmonary Medicine, Malmö University Hospital
Malmo, , Sweden
Department of Pulmonary Medicine, Örebro University Hospital
Örebro, , Sweden
Department of Medicine, Skövde Hospital/KSS
Skövde, , Sweden
Department of Medicine, Trollhättan Hospital/NÄL
Trollhättan, , Sweden
Department of Medicine, Uddevalla Hospital
Uddevalla, , Sweden
Department of Pulmonary medicine, Umeå University Hospital
Umeå, , Sweden
Department of Pulmonary Medicine and Allergology, Uppsala University Hospital
Uppsala, , Sweden
Department of Medicine, Ystad Hospital
Ystad, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Koch A, Bergman B, Holmberg E, Sederholm C, Ek L, Kosieradzki J, Lamberg K, Thaning L, Ydreborg SO, Sorenson S; Swedish Lung Cancer Study Group. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer. 2011 Jul;47(10):1546-55. doi: 10.1016/j.ejca.2011.03.035. Epub 2011 May 10.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SLCSG0501
Identifier Type: -
Identifier Source: org_study_id